RNA therapeutics biotech Prosensa files for a $60 million IPO

By
A A A

Prosensa Holding, a biotech engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders, filed on Friday with the SEC to raise up to $60 million in an initial public offering. The Leiden, Netherlands-based company, which was founded in 2002 and booked $11 million in licensing and collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol RNA. Prosensa Holding initially filed confidentially on April 16, 2013. J.P. Morgan and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

88,615,972
  • $18.16 ▲ 1.57%
86,248,119
  • $31.24 ▼ 14.50%
51,068,934
  • $15.21 ▲ 3.61%
49,661,242
  • $26 ▼ 0.65%
45,376,064
  • $96.99 ▲ 1.78%
43,336,137
  • $35.76 ▲ 1.16%
40,128,160
  • $19.87 ▲ 0.61%
39,636,549
  • $46.29 ▲ 2.10%
As of 7/29/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com